Inmunidad de las Mucosas y Alergia: de la Inmunopatología a la Terapia.
![Foto de Inmunidad de las Mucosas y Alergia: de la Inmunopatología a la Terapia.](/img/uploaded/21C42DF6CDA0E8472C44DA6D4C40ABE3.png)
![Foto de Hospital Universitario de Salamanca](/img/noimage_org.png)
Hospital Universitario de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (18)
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91
-
Incidence, and natural history of inflammatory bowel disease in Castilla y León: Prospective and multicenter epidemiological study
Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 102-108
2022
-
Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)
Journal of Clinical Medicine
-
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Frontiers in Medicine, Vol. 9
-
Novel genes and sex differences in COVID-19 severity
Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806
2021
-
Can the Cytokine Profile According to ABO Blood Groups Be Related to Worse Outcome in COVID-19 Patients? Yes, They Can
Frontiers in Immunology, Vol. 12
-
Evaluation of cytokines as robust diagnostic biomarkers for COVID-19 detection
Journal of Personalized Medicine, Vol. 11, Núm. 7
-
HGF, IL-1α, and IL-27 are robust biomarkers in early severity stratification of COVID-19 patients
Journal of Clinical Medicine, Vol. 10, Núm. 9
-
Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study
Journal of Clinical Medicine, Vol. 10, Núm. 13
2020
-
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry
Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616
2019
-
Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results from the ENEIDA Registry
Inflammatory Bowel Diseases, Vol. 25, Núm. 11, pp. 1862-1870
-
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study
Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500
2018
-
Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology, Vol. 72, Núm. 20, pp. 2457-2467
2017
-
Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study
American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131
2016
-
Incidence, clinical characteristics, and management of psoriasis induced by Anti-TNF therapy in patients with inflammatory bowel disease: A nationwide cohort study
Inflammatory Bowel Diseases, Vol. 22, Núm. 4, pp. 894-901
2014
-
Diagnosis and allergen immunotherapy treatment of polysensitised patients with respiratory allergy in Spain: An Allergists' Consensus
Clinical and Translational Allergy, Vol. 4, Núm. 1
2006
-
Epidemiología de la diabetes tipo 1 en menores de 15 años en las provincias de Castilla y León
Anales de Pediatria, Vol. 65, Núm. 1, pp. 15-21